STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure

Area of Science:

• Cardiology
• Genetics
• Biomarkers

Background:

• B-type natriuretic peptide (BNP) has beneficial cardiovascular effects, including blood pressure reduction and antifibrotic properties.
• Genetic variations in BNP may influence circulating levels and cardiovascular risk.
• Understanding these genetic factors is crucial for developing preventative strategies for heart failure.

Purpose of the Study:

• To investigate the association between the BNP genetic variant rs198389 and circulating BNP levels.
• To examine the relationship between this genetic variant, its effect on BNP levels, and the risk of adverse cardiovascular outcomes in early-stage heart failure.
• To explore the potential implications of BNP genetic testing and BNP-based therapies for heart failure prevention.

Main Methods:

• Genotyping for the BNP genetic variant rs198389.
• Measurement of circulating B-type natriuretic peptide levels.
• Statistical analysis to correlate genotype with BNP levels and cardiovascular event rates in patients with Stage A and B heart failure.

Main Results:

• Carriers of the minor C allele of rs198389 exhibited higher circulating BNP levels.
• These individuals demonstrated a decreased risk of hypertension.
• A reduced risk of new-onset left ventricular systolic dysfunction and hospitalization for major adverse cardiovascular events was observed in C allele carriers.

Conclusions:

• The BNP genetic variant rs198389 influences circulating BNP levels and is associated with a reduced risk of key cardiovascular events in early heart failure.
• These findings highlight the potential role of genetic profiling in identifying individuals at lower risk for certain cardiovascular complications.
• Further investigation into BNP genetic testing and BNP-targeted therapies is warranted for comprehensive heart failure prevention strategies.